ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Novartis Files For Biosimilar In U.S.

by Ann M. Thayer
August 4, 2014 | APPEARED IN VOLUME 92, ISSUE 31

Novartis’s generic drug business Sandoz is seeking FDA approval of a copycat version of Amgen’s white-blood-cell-stimulant drug Neupogen (filgrastim). In 2013, Amgen’s combined sales of Neupogen and a longer-lasting version called Neulasta were $5.8 billion. Novartis says it is the first company to file for review under the biosimilars regulatory pathway created in the Biologics Price Competition & Innovation Act of 2009. FDA’s acceptance of the filing “represents a significant step toward making high-quality biologics more accessible in the U.S.,” says Mark A. McCamish, head of biopharmaceutical and oncology injectables development at Sandoz. The company already sells a version of filgrastim, under the name Zarzio, in more than 40 countries.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment